Kenvue Inc. (NYSE:KVUE) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP trimmed its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 65.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 229,541 shares of the company's stock after selling 439,517 shares during the quarter. Bridgewater Associates LP's holdings in Kenvue were worth $4,901,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of KVUE. Handelsbanken Fonder AB lifted its position in Kenvue by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after acquiring an additional 21,222 shares during the period. Alberta Investment Management Corp boosted its holdings in shares of Kenvue by 23.2% in the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock valued at $12,445,000 after acquiring an additional 109,700 shares in the last quarter. Longbow Finance SA increased its stake in shares of Kenvue by 5.0% during the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company's stock worth $5,990,000 after acquiring an additional 13,287 shares during the period. Steward Partners Investment Advisory LLC raised its holdings in Kenvue by 143.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock worth $1,023,000 after purchasing an additional 28,216 shares in the last quarter. Finally, CORDA Investment Management LLC. lifted its position in Kenvue by 1.4% in the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock valued at $26,754,000 after purchasing an additional 17,466 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Trading Up 3.0 %

NYSE:KVUE traded up $0.69 on Friday, reaching $23.42. The stock had a trading volume of 22,595,142 shares, compared to its average volume of 17,088,173. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a market cap of $44.93 billion, a price-to-earnings ratio of 44.19, a P/E/G ratio of 2.62 and a beta of 1.02. The firm's fifty day moving average is $22.91 and its two-hundred day moving average is $22.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.50%. Kenvue's dividend payout ratio (DPR) is 154.72%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Citigroup increased their price target on shares of Kenvue from $21.00 to $22.00 and gave the company a "neutral" rating in a report on Monday, April 14th. Piper Sandler boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. UBS Group dropped their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Finally, Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $24.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.